Literature DB >> 21709109

Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease.

Roberto Minutolo1, Rajiv Agarwal, Silvio Borrelli, Paolo Chiodini, Vincenzo Bellizzi, Felice Nappi, Bruno Cianciaruso, Pasquale Zamboli, Giuseppe Conte, Francis B Gabbai, Luca De Nicola.   

Abstract

BACKGROUND: Ambulatory blood pressure (BP) measurement allows a better risk stratification in essential hypertension compared with office blood pressure measurement, but its prognostic role in nondialysis chronic kidney disease has been poorly investigated.
METHODS: The prognostic role of daytime and nighttime systolic BP (SBP) and diastolic BP (DBP) in comparison with office measurements was evaluated in 436 consecutive patients with chronic kidney disease. Primary end points were time to renal death (end-stage renal disease or death) and time to fatal and nonfatal cardiovascular events. Quintiles of BP were used to classify patients.
RESULTS: The mean (SD) age of the patients was 65.1 (13.6) years, and the glomerular filtration rate was 42.9 (19.7) mL/min/1.73 m(2); 41.7% of the participants were women, 36.5% had diabetes, and 30.5% had cardiovascular disease. Office-measured SBP/DBP values were 146 (19)/82 (12) mm Hg; daytime SBP/DBP was 131 (17)/75 (11) mm Hg, and nighttime SBP/DBP was 122 (20)/66 (10) mm Hg. During follow-up (median, 4.2 years), 155 and 103 patients reached the renal and cardiovascular end points, respectively. Compared with a daytime SBP of 126 to 135 mm Hg, patients with an SBP of 136 to 146 mm Hg and those with an SBP higher than 146 mm Hg had an increased adjusted risk of the cardiovascular end point (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.13-4.41 and 3.07; 1.54-6.09) and renal death (1.72; 1.02-2.89 and 1.85; 1.11-3.08). Nighttime SBPs of 125 to 137 mm Hg and higher than 137 mm Hg also increased the risk of the cardiovascular end point (HR, 2.52; 95% CI, 1.11-5.71 and 4.00; 1.77-9.02) and renal end point (1.87; 1.03-3.43 and 2.54; 1.41-4.57) with respect to the reference SBP value of 106-114 mm Hg. Office measurement of BP did not predict the risk of the renal or cardiovascular end point. Patients who were nondippers and those who were reverse dippers had a greater risk of both end points.
CONCLUSION: In chronic kidney disease, ambulatory BP measurement and, in particular, nighttime BP measurement, allows more accurate prediction of renal and cardiovascular risk; office measurement of BP does not predict any outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21709109     DOI: 10.1001/archinternmed.2011.230

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  85 in total

1.  Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage.

Authors:  Paul E Drawz; Arnold B Alper; Amanda H Anderson; Carolyn S Brecklin; Jeanne Charleston; Jing Chen; Rajat Deo; Michael J Fischer; Jiang He; Chi-Yuan Hsu; Yonghong Huan; Martin G Keane; John W Kusek; Gail K Makos; Edgar R Miller; Elsayed Z Soliman; Susan P Steigerwalt; Jonathan J Taliercio; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Dawei Xie; Mahboob Rahman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-18       Impact factor: 8.237

Review 2.  Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Juan J Crespo; María T Ríos; Ana Moyá; Francesco Portaluppi
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

3.  Ambulatory aortic blood pressure, wave reflections and pulse wave velocity are elevated during the third in comparison to the second interdialytic day of the long interval in chronic haemodialysis patients.

Authors:  Georgios Koutroumbas; Panagiotis I Georgianos; Pantelis A Sarafidis; Athanase Protogerou; Antonios Karpetas; Pantelis Vakianis; Vassilios Raptis; Vassilios Liakopoulos; Stylianos Panagoutsos; Christos Syrganis; Ploumis Passadakis
Journal:  Nephrol Dial Transplant       Date:  2015-04-28       Impact factor: 5.992

4.  Renal tubulointerstitial damage and salt-sensitive hypertension in chronic kidney disease: is the tubulointerstitium relevant beyond the glomerulus?

Authors:  Kentaro Kohagura; Yusuke Ohya
Journal:  Hypertens Res       Date:  2014-11-27       Impact factor: 3.872

5.  Altered circadian hemodynamic and renal function in cirrhosis.

Authors:  Suthat Liangpunsakul; Rajiv Agarwal
Journal:  Nephrol Dial Transplant       Date:  2017-02-01       Impact factor: 5.992

6.  Taking blood pressure-lowering medications at night.

Authors:  Ricky Turgeon; G Michael Allan
Journal:  Can Fam Physician       Date:  2012-09       Impact factor: 3.275

Review 7.  Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension?

Authors:  Yalcin Solak; Kazuomi Kario; Adrian Covic; Nathan Bertelsen; Baris Afsar; Abdullah Ozkok; Andrzej Wiecek; Mehmet Kanbay
Journal:  Clin Exp Nephrol       Date:  2015-10-22       Impact factor: 2.801

Review 8.  Blood pressure variability, cardiovascular risk, and risk for renal disease progression.

Authors:  Gianfranco Parati; Juan E Ochoa; Grzegorz Bilo
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

Review 9.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Francesco Portaluppi
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

10.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.